‘All drugs need to be safe and efficacious’ is an ideal goal and the objective of the pharmaceutical industry, researchers and the regulatory agencies is to come closer to this goal as much as possible. In the public health scenario the concepts of drug safety takes a higher priority due to a wider application of therapeutics outside of a controlled environment of clinical trials with rare and idiosyncratic effects surfacing with experience.
According to the dictionary definition, the word vulnerable means someone who is “exposed to the possibility of being attacked or harmed, either physically or emotionally”. So who constitutes the vulnerable population in Clinical Research and why do we need to protect them? To answer this question first, let’s take a brief look at the history of research abuse.